Sandy Lamm LLC sold 25,000 Royalty Pharma (RPRX) shares in two trades under a preset plan.
Sandy Lamm LLC, associated with Royalty Pharma's EVP Marshall Urist, sold 25,000 Class A Ordinary Shares of Royalty Pharma (RPRX) on November 16, 2026. The sales were executed in two transactions under a Rule 10b5-1 plan, with weighted-average prices of $69.4701 for 23,592 shares and $69.9941 for 1,408 shares. This insider activity indicates a sale of approximately $1.74 million worth of shares.
At an average of about $68 a share, SCH sold Royalty Pharma (RPRX) stock under a preset trading plan.
SCH Investment Partners LLC, associated with Royalty Pharma's EVP & Chairman, Partnering, Christopher Hite, sold 100,000 Class A ordinary shares of RPRX on November 17, 2026. The shares were sold at a weighted average price of $68.1471 per share under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, the LLC indirectly holds 177,523 shares, while Hite directly holds 23,200 shares.
150,000 shares are proposed for sale under a trading plan at Royalty Pharma (RPRX).
Sandy Lamm LLC, an officer of Royalty Pharma plc (RPRX), has filed a notice of proposed sale for 150,000 Class A ordinary shares, valued at approximately $10.3 million. The sale, expected around November 16, 2026, is being conducted through Merrill Lynch and is intended to comply with a Rule 10b5-1(c) selling plan established on August 7, 2026. Sandy Lamm LLC acquired these shares in a private transaction from the issuer on June 16, 2020.
Performance awards bring 7,122 Royalty Pharma (RPRX) shares to EVP Christopher Hite.
Royalty Pharma plc (RPRX) EVP & Chairman, Partnering, Christopher Hite, acquired 7,122 Class A Ordinary Shares on November 4, 2026, as part of an equity performance award settlement. These shares were acquired indirectly through SCH Investment Partners LLC. Following this transaction, Hite's indirect holdings totaled 277,523 shares, with an additional 23,200 shares held directly.
An LLC received 150,000 Royalty Pharma (RPRX) shares in an exchange with no additional value paid.
Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), reported the indirect acquisition of 150,000 Class A ordinary shares by Sandy Lamm LLC through an exchange of 15,000 LP interests, with no additional value paid. This transaction, dated November 6, 2026, resulted in Sandy Lamm LLC holding 229,412 LP interests and 150,000 Class A shares. Additionally, Urist directly received 5,341 Class A shares on November 4, 2026, as a settlement of Equity Performance Awards.
After acquiring 42,209 award shares, Royalty Pharma (RPRX) CEO holds 1,350,029 directly.
Royalty Pharma plc CEO and Chairman Pablo G. Legorreta acquired 42,209 Class A Ordinary Shares on November 4, 2026, through an exempt acquisition related to Equity Performance Awards. Following this transaction, his direct holdings of Class A Ordinary Shares increased to 1,350,029. Additionally, Legorreta and associated family entities hold substantial amounts of Class B and Class E Ordinary Shares, which are exchangeable into Class A shares, with Class E shares subject to vesting conditions.
CFO entities convert interests into 250,000 Royalty Pharma (RPRX) shares and acquire 7,122 award shares.
Royalty Pharma's EVP & CFO, Terrance P. Coyne, through TPC RP 2021, LLC and TPC RP, LLC, converted limited partnership interests into a total of 250,000 Class A Ordinary Shares on November 6, 2026. Additionally, TPC RP EPA1 LLC acquired 7,122 Class A Ordinary Shares on November 4, 2026, as a settlement for Equity Performance Awards. These transactions were reported in an SEC Form 4 filing.
Royalty Pharma (NasdaqGS:RPRX) Stock Forecast & Analyst Predictions
Royalty Pharma (RPRX) is forecasted to achieve significant growth in earnings and revenue, with analysts increasing price targets due to portfolio momentum and updated guidance. The company's business model, focused on acquiring biopharmaceutical royalties, is considered defensive and uncorrelated with broader market trends. Despite some recent earnings misses, RPRX continues to expand its royalty portfolio through new deals and strategic appointments in AI and international markets, reinforcing its position in the biopharma funding landscape.
FMR can vote 14.1M Royalty Pharma (RPRX) shares, while its reported ownership extends further.
FMR LLC and Abigail P. Johnson have filed an amended ownership report for Royalty Pharma plc (RPRX), indicating a beneficial ownership of 19,288,880.43 Class A common shares, representing 4.3% of the class. FMR LLC holds sole voting power over 14,091,863.23 shares and sole dispositive power over the full beneficial amount, while Abigail P. Johnson has sole dispositive power over the same amount but no sole voting power. The filing also notes that other persons have rights to dividends or sale proceeds, though no single other interest exceeds 5%.
Royalty Pharma's Depth and Diversification Support Optimistic Outlook and Fair Value Estimate Lift
Royalty Pharma's unique business model, which involves buying biopharmaceutical royalties rather than incurring high R&D or manufacturing costs, supports an optimistic outlook. The company's diversified portfolio across various therapeutic areas further differentiates it from typical biotech firms. This depth and diversification have led to a lift in its fair value estimate despite some recent disappointments like Pelacarsen.
A $150M noncash royalty write-down accompanies lower Q3 profit at Royalty Pharma (RPRX).
Royalty Pharma plc reported a significant drop in Q3 2026 net income to $144.7 million, down from $284.2 million in the prior year, primarily due to a $150.4 million noncash impairment charge on its pelacarsen royalty asset. This impairment followed Novartis' announcement that its Phase 3 trial for pelacarsen did not meet its primary endpoint. Despite the profit decline, total income and other revenues increased to $690.1 million from $609.3 million year-over-year.
Weekly Recap: BeOne Medicines funding in Asia and Q4 2026 $0.235 dividend
Royalty Pharma Plc (NASDAQ:RPRX) has expanded its oncology royalty financing in Asia by funding BeOne Medicines for the commercialization of Amgen’s lung cancer drug in China and other Asian markets. Additionally, Royalty Pharma declared a Q4 2026 dividend of $0.235 per Class A share, payable on December 10, 2026, to shareholders of record as of November 13, 2026.
Royalty Pharma EVP Marshall Urist sells $235,594 in shares By Investing.com
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 4,126 Class A Ordinary Shares worth $235,594 on October 5, 2026, executed under a Rule 10b5-1 trading plan. This sale occurred after Royalty Pharma shares delivered a 61% return over the past year, with the stock currently considered overvalued according to InvestingPro analysis. Despite the sale, Royalty Pharma recently reported strong Q2 2026 results and raised its full-year outlook, leading to increased price targets from BofA Securities and TD Cowen.
Royalty Pharma declares $0.235 dividend for Q4 2026, payable December 10
Royalty Pharma plc announced a dividend of $0.235 per Class A share for the fourth quarter of 2026. The dividend is scheduled to be paid on December 10, 2026, to shareholders of record by November 13, 2026. This move highlights the company's commitment to shareholder value, with its Q3 2026 financial results expected on November 4, 2026.
Royalty Pharma declares fourth quarter 2026 dividend
Royalty Pharma plc has announced that its board of directors has approved a dividend of $0.235 per Class A ordinary share for the fourth quarter of 2026. The dividend is scheduled to be paid on December 10, 2026, to shareholders who are on record as of the close of business on November 13, 2026. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation within the biopharmaceutical industry.
Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share
Royalty Pharma plc has declared a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on December 10, 2026, to shareholders of record as of November 13, 2026. The company, established in 1996, specializes in purchasing biopharmaceutical royalties and supports industry innovation by collaborating with various partners. Royalty Pharma boasts a diverse portfolio of royalties from over 35 commercial products and also funds late-stage clinical trials and product launches.
Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share
Royalty Pharma plc has declared a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on December 10, 2026, to shareholders of record as of November 13, 2026. The company, a major buyer of biopharmaceutical royalties, highlighted its robust portfolio of over 35 commercial products and its role in funding innovation. Despite insider sales, institutional investors showed mixed activity, and analysts issued positive ratings with a median price target of $58.0.
Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10.
Royalty Pharma (Nasdaq: RPRX) has announced a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on December 10, 2026, to shareholders of record as of November 13, 2026. The company, founded in 1996, is a major buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry.
Global femtech market to reach $255.5B by 2035, driven by AI, telehealth, and personalized women's healthcare.
The global femtech market is projected to reach $255.5 billion by 2035, growing from $66.2 billion in 2025 at a CAGR of 14.9%. This significant growth is attributed to the integration of digital technologies like AI, telehealth, and wearable devices, which enhance personalized care for women across various health areas. North America currently leads the market, and key players are expanding through AI-driven personalization, direct-to-consumer models, and strategic partnerships.
Form 4 Royalty Pharma Plc For: 12 October By Investing.com
The article reports on a Form 4 filing for Royalty Pharma Plc (RPRX) dated October 12, published by Investing.com. It mentions that the stock symbol RPRX is down 2.09% and provides a general financial markets context. The content itself is very brief, primarily serving as a placeholder for the actual Form 4 details.
Royalty Pharma EVP Marshall Urist sells $235,594 in shares
Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc, sold 4,126 Class A Ordinary Shares totaling $235,594 on October 5, 2026, through a Rule 10b5-1 trading plan. Following this transaction, Urist directly holds no Class A Ordinary Shares but maintains significant indirect holdings through an IRA and limited partnership interests. The sale occurs after Royalty Pharma shares saw a 61% return over the past year, with the company recently raising its full-year outlook and receiving positive analyst price target adjustments.
Form 4 Royalty Pharma Plc For: 12 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Royalty Pharma Plc (RPRX) on October 12, 2026. The brief entry provides the company's stock symbol and a slight positive change in its stock value. The core content is the announcement of the Form 4 filing.
Royalty Pharma to release Q3 2026 earnings on N...
Royalty Pharma announced it will release its third-quarter 2026 financial results on November 4, 2026, before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. Eastern Time. The company, a significant buyer of biopharmaceutical royalties, holds a portfolio of royalties on over 35 commercial products and 17 development-stage candidates. As of October 9, 2026, its Class A shares traded at USD 56.20 with a market capitalization of $25.27 billion and a 1.66% dividend yield.
At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares.
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 4,126 Class A Ordinary Shares at $57.10 per share on October 5, 2026. This transaction was conducted under a Rule 10b5-1 plan adopted in June 2026, resulting in a direct holding of 0 shares post-sale, though he indirectly holds 19,020 shares via an IRA. The sale of shares totaled approximately $236,000.
Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares.
Royalty Pharma officer Marshall Urist has proposed selling 4,126 Class A ordinary shares of RPRX, valued at approximately $235,594.60, through Merrill Lynch with an approximate sale date of October 5, 2026. These shares originated from an equity performance award granted on August 7, 2026. Urist has also completed previous sales of RPRX shares in July and September 2026.
Form 4 Royalty Pharma Plc For: 30 September By Investing.com
This article announces the filing of a Form 4 for Royalty Pharma Plc for the period ending September 30. It includes the publication date and time, the company's stock symbol (RPRX), and a brief mention of its current performance (-1.14%). The content primarily consists of financial market data and popular news headlines from Investing.com.
Weekly Recap: Q2 royalties up 14% and Novartis pelacarsen Phase 3 failed
Royalty Pharma Plc (RPRX) experienced a surge to a 52-week high after reporting strong Q2 royalty receipts and raising its guidance. However, these gains were partially offset by the failure of Novartis's Phase 3 Horizon trial for pelacarsen, which impacts RPRX's expected near-term royalties from the drug.
Form 4 Royalty Pharma Plc For: 30 September By Investing.com
This article reports on the filing of Form 4 by Royalty Pharma Plc for the period ending September 30. It includes a brief mention of the company's stock symbol RPRX and its performance. The content is primarily a placeholder for the Form 4 details, presented within the Investing.com financial news framework.
A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX).
Royalty Pharma plc director Bonnie L. Bassler acquired 642 Class A Ordinary Shares on September 30, 2026. This acquisition was made under the 2020 Independent Director Equity Incentive Plan as a quarterly retainer payment of $37,500. Following this transaction, her direct holdings in the company totaled 79,823 shares.
4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist.
Royalty Pharma EVP Marshall Urist sold 4,126 Class A Ordinary Shares at $57.88 per share on September 28, 2026, under a prearranged Rule 10b5-1 trading plan. After the transaction, Urist directly held 4,126 shares and indirectly held 19,020 shares through an IRA. The sale was reported in a Form 4 filing, which also detailed additional indirect holdings via limited partnership interests and Class E Ordinary Shares subject to vesting.
Form 4 Royalty Pharma Plc For: 30 September By Investing.com
This article reports on the filing of Form 4 by Royalty Pharma Plc for the period ending September 30. It's a brief announcement from Investing.com, providing basic financial news without additional details in the content. The report confirms the filing with the stock symbol RPRX mentioned.
Royalty Pharma EVP Marshall Urist sells $238,812 in shares
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 4,126 Class A Ordinary Shares worth $238,812 on September 28, 2026, through a pre-arranged 10b5-1 trading plan. This transaction follows strong performance by Royalty Pharma shares and comes amidst the company reporting robust Q2 2026 financial results and a thriving biotech funding environment.
Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD
This article provides financial data specifically focusing on the operating cash flow per share of Royalty Pharma Plc Class A (HAN:RPD) on the Hannover Stock Exchange. The content is primarily a data display with no additional textual analysis or details beyond the stock information. It appears to be a snapshot from a financial tracking platform.
Royalty Pharma officer proposes $239K share sale | RPRX SEC Filing - Form 144
Royalty Pharma plc (RPRX) officer Marshall Urist has proposed selling 4,126 Class A ordinary shares, valued at $238,812.88, through Merrill Lynch on September 28, 2026. These shares originated from an equity performance award granted on August 5, 2026. The filing also discloses four previous common-stock sales by Urist between May and July 2026, totaling over $2.4 million.
Royalty Pharma EVP Christopher Hite sells $5.85m in shares
Royalty Pharma's EVP Christopher Hite sold 100,000 Class A ordinary shares for approximately $5.85 million on September 22, 2026, executed under a pre-arranged trading plan. This insider sale occurs as Royalty Pharma shares have seen a 70% return over the past year, though InvestingPro analysis suggests the stock is currently overvalued. Hite retains significant indirect ownership and other interests in the company.
Form 4 Royalty Pharma Plc For: 25 September By Investing.com
This article from Investing.com announces the filing of a Form 4 for Royalty Pharma Plc on September 25. The content primarily consists of market data, news headlines, and various financial tool advertisements typical of a financial news platform.
A prearranged plan governed SCH Investment Partners’ sale of 100,000 Royalty Pharma (RPRX) shares.
SCH Investment Partners LLC, controlled by Royalty Pharma's EVP & Chairman, Partnering Christopher Hite, sold 100,000 Class A ordinary shares of Royalty Pharma (RPRX) on September 22, 2026. These sales, totaling approximately $5.85 million, were executed under a pre-arranged Rule 10b5-1 plan adopted on March 20, 2026. Following the transactions, Hite directly holds 23,200 shares, with family vehicles holding additional exchangeable interests.
Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com
Royalty Pharma's EVP Christopher Hite sold 100,000 Class A ordinary shares for approximately $5.85 million, executed under a 10b5-1 trading plan. This insider sale follows a 70% return for Royalty Pharma shares over the past year, though the stock is considered overvalued by InvestingPro. The company recently reported strong Q2 2026 results and raised its outlook, leading to increased price targets from BofA Securities and TD Cowen despite some royalty adjustments.
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares
SCH Investment Partners LLC plans to sell 100,000 Class A Ordinary Shares of Royalty Pharma plc (RPRX) with an aggregate market value of approximately $5.8 million through Merrill Lynch, as detailed in a recent SEC Form 144 filing. This follows previous sales of 350,000 Class A Ordinary Shares by the same entity over the past three months under a Rule 10b5-1(c) selling plan. The shares for the new sale were acquired in a private transaction on May 13, 2024.
Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Price, Quote, News & History
This page provides stock price information, quotes, news, and historical data for Royalty Pharma plc Class A Ordinary Shares (RPRX) on Nasdaq. It includes details on bid/ask prices, data disclaimers, and emphasizes that key data is currently unavailable. The content highlights the importance of bid-ask spread for liquidity and order execution.
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week High - What's Next?
Royalty Pharma (NASDAQ:RPRX) recently achieved a new 52-week high of $62.58, with analysts maintaining a "Buy" rating and an average target price of $60.86. Despite revenue missing estimates, the company surpassed EPS expectations in its latest quarterly results. Royalty Pharma also announced a quarterly dividend of $0.235 per share, though insiders have sold a significant amount of stock recently.
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX
Headlands Technologies LLC has acquired a new stake in Royalty Pharma PLC, purchasing 90,729 shares valued at approximately $5.09 million during the second quarter. Other institutional investors have also increased their holdings in the biopharmaceutical company, which has reported quarterly EPS of $1.32, beating estimates, despite revenue falling short of consensus forecasts. Analysts generally maintain a positive outlook for Royalty Pharma, with an average price target of $60.86.
Odyssean LLC Acquires 21,401 Shares of Royalty Pharma PLC $RPRX
Odyssean LLC increased its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 65.3% in Q2 2026, acquiring an additional 21,401 shares, bringing its total holdings to 54,179 shares valued at $3.04 million. The biopharmaceutical company reported Q2 EPS of $1.32, surpassing estimates, though revenue of $674.14 million missed expectations. Analysts maintain a bullish outlook with an average price target of $60.86, and Royalty Pharma declared a quarterly dividend of $0.235, representing a 1.5% annualized yield.
RPRX | Royalty Pharma plc Class Financials - Revenue Breakdown
This article provides a detailed financial overview of Royalty Pharma plc (RPRX), focusing on its revenue breakdown and other key financial metrics. It includes sections on insider trading, institutional holdings, analyst ratings, and information about the company's business model as the largest buyer of biopharmaceutical royalties. The report highlights the absence of specific revenue breakdown by segment or geography, congressional trading data, corporate lobbying instances, and recent patent grants for RPRX.
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 11,002 Class A Ordinary Shares worth $645,551 on August 13, 2026, through a pre-arranged trading plan. The sales occurred as the stock traded near its 52-week high, with shares up 67% over the past year. Despite the sales, Coyne retains significant beneficial ownership through direct holdings and various indirect interests.
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock
Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma (RPRX), reported insider activity including the sale of 100,000 Class A Ordinary Shares by an associated entity, SCH Investment Partners LLC, at a weighted average price of $59.9725 per share. The sale was executed under a Rule 10b5-1 trading plan. Additionally, Hite made a charitable gift of 16,800 Class A Ordinary Shares to Lehigh University, impacting his direct and indirect holdings in the company.
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity
Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc, sold 100,000 Class A Ordinary Shares for approximately $5.99 million under a 10b5-1 trading plan. Additionally, he donated 16,800 shares to Lehigh University. Following these transactions, Hite retains significant direct and indirect ownership in the company.
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale
SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma (NASDAQ: RPRX) with an aggregate market value of $6,012,000. These shares were acquired in private transactions in 2024 and 2025 and represent a small fraction of Royalty Pharma's 445,277,344 outstanding shares. The planned sale is part of a pre-arranged selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c), and follows previous sales by SCH Investment Partners LLC in June 2026.
Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated
Pablo Legorreta has updated his beneficial ownership in Royalty Pharma (NASDAQ: RPRX) through an amended SEC filing, reporting a stake of 101.8 million Class A shares, representing 18.73% of the class. This includes shares issuable under an A&R Exchange Agreement, and the recalculation follows a change in the number of outstanding Class A shares. The filing also details recent equity transactions, including the acquisition of shares from performance awards and a gift of partnership interests.
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares
Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold 11,002 Class A Ordinary Shares totaling $645,551 on August 13, 2026, under a Rule 10b5-1 trading plan. The shares were sold in multiple transactions at prices ranging from $57.99 to $59.52. Despite this insider sale, Royalty Pharma recently reported strong Q2 2026 results with increased royalty receipts and a raised full-year outlook, leading BofA Securities to increase its price target.